Navigate Fool.com
Will IDIX beat
the market?
Community Rating: 2 Stars: Unattractive

5.67 -0.27 (-4.55%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.93
Previous Close $5.94
Daily Range $5.54 - $5.94
52-Week Range $2.93 - $9.32
Market Cap $855.1M
P/E Ratio -6.53
Dividend (Yield) $0.00 (0.0%)
Volume 296,763
Average Daily Volume 1,493,743
Current FY EPS -$0.83

How do you think IDIX
will perform against the market?

Top IDIX Bull/Bear Pitches


darkflame (< 20)
Submitted April 15, 2007

What company is this ? Well...it's a small biotec company, Novartis owns more than 10% of it and isnt selling any shares. Novartis bought more than 4 million shares of IDIX at a price over 20 dollars … More

2 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted December 17, 2007

After the recent restructuring, it is now clear where this company stands. One HIV drug in phase I with no current plan for a phase II trial. One or two HCV drugs in preclinical development, with a hi … More

1 Replies Reply Report this Post

News & Commentary

Why Idenix Pharmaceuticals, B&G Foods, and Petrobras Rose Today

The stock market plunged again on fears of a further correction, but these stocks still managed to post solid gains Monday. Find out more about what sent them higher.

Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit Outlook

MannKind vs. Idenix: Better Biotech Buy

What's the better buy in biotech today?

Why Idenix Pharmaceuticals Inc. Shares Jumped

Idenix shares roar higher after provided data and an update to its nucleotide prodrug inhibitor program. However, here's what shareholders should really be concerned about.

Geron Held Up

Will Geron follow the same fate as Idenix Pharmaceuticals and Bristol-Myers Squibb, or can it overcome the FDA's clinical hold.

Trouble Ahead for Gilead and Sovaldi?

Idenix files suit atop $9 billion sales estimates for Gilead's Sovaldi

Interesting IDIX Put And Call Options For October 18th

Gilead and Celgene Down: Could the Whole Biotech Sector Follow?

Top healthcare stocks have started to pull back in a big way in recent sessions. Could this be the beginning of a sector wide correction?

Today's Top Biotech Stories: Five Prime, Bristol-Myers Squibb, Intercept, and Gilead Sciences

Five Prime, Bristol-Myers Squibb, Intercept Pharmaceuticals, and Gilead Sciences could be the top biotech stories to follow this morning. Here's why.

Aeropostale slides; Liberty Media drops Sirius plan

See More IDIX News...





Idenix Pharmaceuticals, Inc. (IDIX) Description

A biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases with operations in the United States and Europe. Website: http://www.idenix.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks